Vaccine stocks slipped in late afternoon trade on Thursday after multiple reports indicated President-elect Donald Trump would name anti-vaccine activist Robert F. Kennedy Jr. to lead the Department ...

Oct 16 (Reuters) - Moderna (MRNA.O), opens new tab was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren from TD Cowen maintained a Hold rating on the stock and has ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of $38.00. Mani Foroohar’s rating is based on several ...

The greenback hovered near a one-year high against a basket of currencies at 106.88, eyeing a weekly gain of 1.8%, which would mark its best performance since September.

Trump's AG Pick Matt Gaetz Once Proposed Collecting Federal Income Taxes In Bitcoin, Along With Co-sponsoring Bill To Abolish The Fed President-elect Donald Trump has picked Rep. Matt Gaetz (R-Fla.) ...

Moderna earned $5.4 billion in U.S. revenues in 2021 and $4.4 billion in 2022 from COVID-19 vaccine sales. Northwestern University’s nanotechnology research institute, IIN, has supported over $2 ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Northwestern University filed a patent infringement ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus, or RSV, in adults 60 years and older, making it the country's first authorized mRNA-based ...

“Years later, this breakthrough would be the key to delivering Moderna’s mRNA vaccine into the targeted cells that would trigger an immune response in the body.” – Northwestern complaint ...

The stock price of Moderna has seen a sharp 48% fall this year. From its lows of around $50, it is expected to see a rebound after posting a solid Q3 beat. The company reported revenue of $1.86 ...